What's Happening?
Osteoboost Health has successfully closed an $8 million financing round led by Ambit Health Ventures, with participation from several other investment firms. The funds will support the expansion of Osteoboost's
FDA-cleared device, which is designed to address osteopenia, a precursor to osteoporosis affecting nearly 44 million Americans. The device, a wearable belt, delivers targeted vibration therapy to the lumbar spine and hips, areas most vulnerable to fracture. Inspired by NASA-funded research, clinical trials have shown the device can slow bone density loss significantly, offering a non-drug treatment option for postmenopausal women.
Why It's Important?
The Osteoboost device represents a significant advancement in the treatment of osteopenia, a condition that currently lacks approved drug therapies. With bone density loss accelerating during menopause, the device offers a proactive solution beyond traditional calcium and exercise regimens. The funding will enable Osteoboost to expand its reach, potentially improving bone health for millions of Americans. This development is crucial as it addresses a significant gap in women's health, a sector that receives limited private healthcare capital despite high demand.
What's Next?
Osteoboost plans to use the funding to further develop its bone health ecosystem, including a video training platform that has shown promising results in improving lower-body strength and reducing fall risk. The company aims to increase its presence in academic medical centers and expand its prescription base, potentially influencing the standard of care for osteopenia. As the device gains traction, it may lead to broader acceptance and integration into healthcare practices, offering a new avenue for managing bone density issues.
